Quick Answer
Galera Therapeutics, Inc. reported Total Assets of $7.20 million for the year ending 2025.
- Galera Therapeutics, Inc. showed a decrease of -28.8% in Total Assets from 2024 to 2025.
- This data is from Galera Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $79.76 million | Q1 2020: $130.81 million | Q2 2020: $114.30 million | Q3 2020: $98.08 million | Q1 2021: $70.49 million | Q2 2021: $115.27 million | Q3 2021: $98.77 million | Q1 2022: $71.10 million | Q2 2022: $61.08 million | Q3 2022: $50.71 million | Q1 2023: $59.71 million | Q2 2023: $48.28 million | Q3 2023: $37.78 million | Q1 2024: $19.65 million | Q2 2024: $16.38 million | Q3 2024: $8.90 million | Q1 2025: $7.66 million | Q2 2025: $6.05 million | Q3 2025: $5.00 million.
- Over the full 8 years of available data (2018 to 2025), Galera Therapeutics, Inc.'s Total Assets has declined by 91.8%.
- Historical annual values: Fiscal year 2025: $7.20 million | Fiscal year 2024: $10.10 million | Fiscal year 2023: $26.14 million | Fiscal year 2022: $44.04 million | Fiscal year 2021: $83.31 million | Fiscal year 2020: $84.10 million | Fiscal year 2019: $123.38 million | Fiscal year 2018: $88.06 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: